JPH0522689B2 - - Google Patents
Info
- Publication number
- JPH0522689B2 JPH0522689B2 JP59106301A JP10630184A JPH0522689B2 JP H0522689 B2 JPH0522689 B2 JP H0522689B2 JP 59106301 A JP59106301 A JP 59106301A JP 10630184 A JP10630184 A JP 10630184A JP H0522689 B2 JPH0522689 B2 JP H0522689B2
- Authority
- JP
- Japan
- Prior art keywords
- herpes
- adenosine
- treatment
- ointment
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 60
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 29
- 229960005305 adenosine Drugs 0.000 claims abstract description 29
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 239000002674 ointment Substances 0.000 claims description 20
- 208000004898 Herpes Labialis Diseases 0.000 claims description 7
- 208000007514 Herpes zoster Diseases 0.000 claims description 7
- 206010067152 Oral herpes Diseases 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 2
- 201000004946 genital herpes Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract description 5
- 230000007935 neutral effect Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- -1 PHB ester Chemical class 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940079920 digestives acid preparations Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/001—Preparations for care of the lips
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Communicable Diseases (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3319282.0 | 1983-05-27 | ||
| DE19833319282 DE3319282A1 (de) | 1983-05-27 | 1983-05-27 | Verwendung von adenosin bei der behandlung von herpes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS604130A JPS604130A (ja) | 1985-01-10 |
| JPH0522689B2 true JPH0522689B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-03-30 |
Family
ID=6200045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59106301A Granted JPS604130A (ja) | 1983-05-27 | 1984-05-25 | アデノシン含有医薬製剤 |
Country Status (5)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3319282A1 (de) * | 1983-05-27 | 1984-11-29 | Gödecke AG, 1000 Berlin | Verwendung von adenosin bei der behandlung von herpes |
| US4853373A (en) * | 1986-09-15 | 1989-08-01 | Livingston William S | Therapeutic treatment for arthritic condition |
| ZA888083B (en) * | 1987-10-28 | 1990-06-27 | Pro Neuron Inc | Acyl deoxyribonucleoside derivatives and uses thereof |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US7169765B1 (en) | 1988-10-27 | 2007-01-30 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| DE19545107A1 (de) * | 1995-12-04 | 1997-06-05 | Beiersdorf Ag | Verwendung eines wirksamen Gehaltes an Adenosin in kosmetischen oder dermatologischen Zubereitungen |
| DE19832519A1 (de) * | 1998-07-20 | 2000-01-27 | Hartmut Oswald | Arzneimittelzubereitungen zur topischen Behandlung mukokutaner Herpesinfektionen sowie der Keratitis herpetica des Auges |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| US7618950B2 (en) * | 2004-07-07 | 2009-11-17 | Arigen Pharmaceuticals, Inc. | Method for treatment and prevention of herpes zoster by topical application |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US7790203B2 (en) * | 2005-12-13 | 2010-09-07 | Lowder Tom R | Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions |
| US20090197892A1 (en) * | 2007-08-21 | 2009-08-06 | Nawaz Ahmad | Anhydrous compositions useful for attaining enhanced sexual wellness |
| DE102011005232A1 (de) * | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1440795A (fr) * | 1965-04-21 | 1966-06-03 | Docteur Jacques Auclair Lab Du | Composition cosmétique |
| BE759011A (fr) * | 1969-11-17 | 1971-05-17 | Wellcome Found | Aminopurines |
| DE2330902A1 (de) * | 1973-06-18 | 1975-03-20 | Helmut Dr Med Zander | Heilungsfoerderndes und vorbeugendes, zur aeusserlichen oertlichen anwendung auf der haut und im auge fuer mensch und tier bestimmtes arznei- bzw. hautpflegemittel |
| US3948883A (en) * | 1974-11-11 | 1976-04-06 | The Salk Institute For Biological Studies | Synthesis of purine nucleosides |
| US4044122A (en) * | 1976-01-27 | 1977-08-23 | Sklar S Harvey | Method of treating herpes virus hominis infections |
| FR2358155A1 (fr) * | 1976-07-15 | 1978-02-10 | Lapinet Eugene | Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses |
| GB2080682B (en) * | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
| DE3319282A1 (de) * | 1983-05-27 | 1984-11-29 | Gödecke AG, 1000 Berlin | Verwendung von adenosin bei der behandlung von herpes |
-
1983
- 1983-05-27 DE DE19833319282 patent/DE3319282A1/de active Granted
-
1984
- 1984-05-25 AT AT84105992T patent/ATE26213T1/de not_active IP Right Cessation
- 1984-05-25 DE DE8484105992T patent/DE3462852D1/de not_active Expired
- 1984-05-25 EP EP84105992A patent/EP0127160B1/de not_active Expired
- 1984-05-25 JP JP59106301A patent/JPS604130A/ja active Granted
-
1989
- 1989-05-25 US US07/357,691 patent/US5034382A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3319282C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-01-28 |
| EP0127160B1 (de) | 1987-04-01 |
| DE3319282A1 (de) | 1984-11-29 |
| ATE26213T1 (de) | 1987-04-15 |
| JPS604130A (ja) | 1985-01-10 |
| US5034382A (en) | 1991-07-23 |
| DE3462852D1 (en) | 1987-05-07 |
| EP0127160A1 (de) | 1984-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| US9387227B2 (en) | Method for treatment of sores and lesions of the skin | |
| EP1064946B1 (en) | Topical zinc compositions | |
| EP0809498B1 (en) | Pharmaceuitical composition for topical application containing acyclovir and hydrocortisone | |
| CA1273576A (en) | Topical treatment for diseased skin disorders | |
| US6350785B2 (en) | Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors | |
| CA1083040A (en) | Topical application of medication by ultrasound with coupling agent | |
| CA2301009C (en) | Skin care compositions and use | |
| JPH0522689B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US5420114A (en) | Methods for the treatment of skin disorders | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| JPH039885B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2097016C1 (ru) | Лечебно-профилактический гигиенический противогерпетический крем | |
| JPH04501851A (ja) | 脱毛症治療のためのミノキシジルおよび血管収縮薬組成物 | |
| NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
| JPH0429934A (ja) | いちょう葉抽出エキスを含有する外用組成物 | |
| KR20140041476A (ko) | 바이러스 감염의 치료 | |
| CA2126704C (en) | Dermatological compositions and methods for the treatment of skin therewith | |
| US5977176A (en) | Compositions for the treatment of warts and herpes | |
| WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
| JPH039883B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS58134022A (ja) | 色素増強疾患治療剤 | |
| JPS59184127A (ja) | ヘルペスウイルスによる病気の治療 | |
| JPS6234015B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| HK1004368B (en) | Pharmaceutical composition for topical application containing acyclovir and hydrocortisone |